Cargando…
Non-Coding Micro RNAs and Hypoxia-Inducible Factors Are Selenium Targets for Development of a Mechanism-Based Combination Strategy in Clear-Cell Renal Cell Carcinoma—Bench-to-Bedside Therapy
Durable response, inherent or acquired resistance, and dose-limiting toxicities continue to represent major barriers in the treatment of patients with advanced clear-cell renal cell carcinoma (ccRCC). The majority of ccRCC tumors are characterized by the loss of Von Hippel–Lindau tumor suppressor ge...
Autores principales: | Rustum, Youcef M., Chintala, Sreenivasulu, Durrani, Farukh A., Bhattacharya, Arup |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6275006/ https://www.ncbi.nlm.nih.gov/pubmed/30380599 http://dx.doi.org/10.3390/ijms19113378 |
Ejemplares similares
-
Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition
por: Chintala, Sreenivasulu, et al.
Publicado: (2012) -
Current Landscape and the Potential Role of Hypoxia-Inducible Factors and Selenium in Clear Cell Renal Cell Carcinoma Treatment
por: Garje, Rohan, et al.
Publicado: (2018) -
Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development
por: Zakharia, Yousef, et al.
Publicado: (2018) -
Non-coding RNAs in Rheumatoid Arthritis: From Bench to Bedside
por: Wang, Jinghua, et al.
Publicado: (2020) -
Architectural Heterogeneity in Tumors Caused by Differentiation
Alters Intratumoral Drug Distribution and Affects Therapeutic Synergy of Antiangiogenic Organoselenium Compound
por: Rustum, Youcef M., et al.
Publicado: (2010)